Tech Company Financing Transactions
KemPharm Funding Round
On 6/4/2014, KemPharm raised $60 million in investment from Deerfield Capital.
Transaction Overview
Company Name
Announced On
6/4/2014
Transaction Type
Debt
Amount
$60,000,000
Round
Undisclosed
Investors
Deerfield Capital (Jonathan Leff)
Proceeds Purpose
Plans to use the proceeds to fund its clinical, regulatory and operational growth, and, most notably, to advance its lead product candidate, KP201 (benzhydrocodone hydrochloride and acetaminophen), through potential FDA approval and into commercial development.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1180 Celebration Blvd. 103
Celebration, FL 34747
USA
Celebration, FL 34747
USA
Phone
Website
Email Address
Overview
KemPharm, Inc. is an early phase biopharmaceutical company located in the Iowa City, IA area near the campus of the University of Iowa. We are focused on the discovery and development of new, safer therapies for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), pain, and cardiovascular disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Travis Mickle
Chief Financial Officer
LaDuane Clifton
Vice President
Rene Braeckman
VP - Bus. Development
Gordon Johnson
VP - Manufacturing
Christopher Lauderback
VP - Operations
Christal Mickle
VP - R & D
Sven Guenther
VP - Regulatory Affairs
Andrew Barrett
Browse more venture capital transactions:
Prev: 6/4/2014: InDemand Interpreting venture capital transaction
Next: 6/4/2014: Fresh Nation venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site come from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs